Description
Recombinant monoclonal antibody to ganglioside GD3. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma KM8871. This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques.
Target
ganglioside GD3
Target Alias Names
ganglioside, C68H121N3O29, (2S, 4S, 5R)-5-acetamido-6-[(1S, 2R)-2-[(2S, 4S, 5R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R, 2R)-1, 2, 3-trihydroxypropyl]oxan-2-yl]oxy-1, 3-dihydroxypropyl]-2-[(2S, 3R, 4S, 5S, 6R)-2-[(2R, 3S, 4R, 6R)-6-[(E, 2S, 3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-4, 5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3, 5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid, CHEBI:89636, d18:1/20:0
Isotype/Mimetic
IgG1
Animal-Derived Biomaterials Used
No
Sequence Available
No
Original Discovery Method
recombinantly reformatted hybridoma (from pre-2020 immunisation)
Original Discovery Information Provided On Datasheet
Yes
Antibody/Binder Origins
Animal-dependent discovery (in vitro display, OR immunisation pre-2020), In vitro recombinant expression